Health Care • Biotechnology: Pharmaceutical Preparations
$7.90 ▲ +0.30
(+3.95%)
MKT CAP: $516.6M • VOL: 863.8K
52W L $7 52W H $15
ARVN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $262.6M | $263.4M | $78.5M |
| YoY Revenue Growth % | -0.3% | +235.5% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$118.5M | -$250.2M | -$401.5M |
| Operating Margin % | -45.1% | -80.0% | -80.0% |
| Net Income (GAAP) | -$81.0M | -$199.0M | -$367.0M |
| EBITDA (Normalized) | -$117.0M | -$248.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$273.8M | -$259.3M | -$347.8M |
| Capital Expenditures (CapEx) | $1.9M | $1.8M | — |
| Free Cash Flow (FCF) | -$275.7M | -$261.1M | -$347.8M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -32.1% | -42.8% | — |
| Cash & Short-Term Equivalents | $142.9M | $100.5M | — |
| Total Debt (Short + Long Term) | $400.0K | $600.0K | — |
| Total Stockholders' Equity | $433.9M | $561.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ARVN.